Skip to main content

Table 2 Laboratory findings, prevalence of lipid disorder and treatments in both groups

From: Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study

Study GroupYoung Age GroupElderly Age GroupP
Total Number (n)4941657 
Reported Lipid Disorder2.6%37.1%<0.01
Laboratory findings
Total Cholesterol, median (IQR (interquartile range)), mmol/L4.5 (4.0 – 5.1)5.6 (4.9 – 6.3)<0.01
LDL-Cholesterol, median (IQR), mmol/L2.5 (2.0 – 3.0)3.4 (2.8 – 4.0)<0.01
HDL-Cholesterol, median (IQR),all, mmol/L1.5 (1.3 – 1.8)1.6 (1.3 – 1.9)0.097
HDL-Cholesterol, median (IQR), by sex, mmol/Lfemale 1.8 (1.5–2.0)male 1.4 (1.1-1.6)female 1.8 (1.5-2.0)male 1.4 (1.1-1.7)<0.01/<0.01
Lipoprotein(a), median (IQR), mg/dL7.0 (1.5 – 21.0)11.0 (4.6 – 33.9)<0.01
Triglycerides, median (IQR), mmol/L0.9 (0.7 – 1.2)1.1 (0.9 – 1.5)<0.01
Any measured Lipid Disorder40.6%76.0%<0.01
- Hypercholesterolemia (Total Cholesterol >= 5.2 mmol/L)23.7%64.0%<0.01
- Hypertriglyceridemia (Triglycerides >= 2.3 mmol/L)3.5%6.8%<0.01
- Combined Hyperlipoproteinaemia (Total Cholesterol >= 5.2 mmol/L and Triglycerides >= 2.3 mmol/L)2.6%4.6%0.054
- Hyperlipoproteinemia(a) (lipoprotein(a) >= 50 mg/dL)7.9%18.3%<0.01
- Low HDL Cholesterol (HDL Cholesterol <1.0 mmol/L in men or <1.3 mmol/L in women), all13.0%11.0%0.238
- Low HDL Cholesterol (HDL Cholesterol <1.0 mmol/L in men or <1.3 mmol/L in women), by sexfemale 11.6%male 14.5%female 9.8%male 12.3%0.342/0.107
- Combined Hypertriglyceridemia and Low HDL Cholesterol2.3%3.1%0.356
Consultation of a general practitioner during the last 3 months35.0%60.3%<0.01
Treated with any lipid-lowering medication0.0%16.8%<0.01
- Statins0.0%16.3%<0.01
- Fibrates0.0%0.2%0.274
- Ezetimibe0.0%1.1%0.02
LDL-treated to target, ESC-Guidelines97.6%7.4%<0.01
  1. Abbreviations: ESC: European Society of Cardiology, GFR: glomerular filtration rate, HDL: high density lipoprotein, IQR: interquartile range, LDL: low density lipoprotein, Lp(a): Lipoprotein(a), SD: standard deviation